Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.
We have shown previously that intraparenchymal infusion of glial cell line-derived neurotrophic factor (GDNF) continuously into the posterior putamen in five Parkinson's disease patients is safe and may represent a new treatment option. Here, we report a continuation of this phase I study. After 2 years of continual GDNF infusion, there were no serious clinical side effects and no significant detrimental effects on cognition. Patients showed a 57% and 63% improvement in their off-medication motor and activities of daily living subscores of the Unified Parkinson's Disease Rating Scale, respectively, and health-related quality-of-life measures (Parkinson's Disease Questionnaire-39 and Short Form-36) showed general improvement over time.
Patel
Nikunj K
NK
Frenchay Hospital, Institute of Neurosciences, Bristol, United Kingdom.
Bunnage
Martin
M
Plaha
Puneet
P
Svendsen
Clive N
CN
Heywood
Peter
P
Gill
Steven S
SS
D000203:Activities of Daily Living; D002408:Catheters, Indwelling; D003071:Cognition; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006801:Humans; D007276:Injections, Intraventricular; D009043:Motor Activity / Q000187:drug effects; D009414:Nerve Growth Factors / Q000008:administration & dosage* / Q000009:adverse effects*; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000188:drug therapy*; D011699:Putamen / Q000187:drug effects*; D011788:Quality of Life; D016896:Treatment Outcome
C495039:GDNF protein, human; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents